miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome

[1]  R. Fonseca,et al.  Chromosome 1q21 abnormalities in multiple myeloma , 2021, Blood Cancer Journal.

[2]  A. Scorilas,et al.  Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background , 2021, International journal of molecular sciences.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  H. Goldschmidt,et al.  Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up , 2021, HemaSphere.

[5]  F. Zhan,et al.  The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma , 2021, Nature Communications.

[6]  Min Liu,et al.  Roles of miRNA dysregulation in the pathogenesis of multiple myeloma , 2021, Cancer gene therapy.

[7]  Kang Liu,et al.  Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma , 2021, Hematology.

[8]  D. Dingli,et al.  Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. , 2020, Blood Advances.

[9]  P. Tassone,et al.  miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma , 2020, Leukemia.

[10]  C. Gross,et al.  Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. , 2020, Blood advances.

[11]  S. Haque,et al.  Silencing of Exosomal miR-181a Reverses Pediatric Acute Lymphocytic Leukemia Cell Proliferation , 2020, bioRxiv.

[12]  S. Rajkumar,et al.  Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management , 2020, American journal of hematology.

[13]  H. Goldschmidt,et al.  Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma , 2020, Blood Cancer Journal.

[14]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[15]  A. Scorilas,et al.  Circulating exosomal miRNAs: clinical significance in human cancers , 2019, Expert review of molecular diagnostics.

[16]  Nisha S Joseph,et al.  Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone , 2019, Blood Cancer Journal.

[17]  Jingyu Yang,et al.  Effects of miR‑181a on the biological function of multiple myeloma. , 2019, Oncology reports.

[18]  P. Tassone,et al.  miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma , 2019, Molecular therapy. Nucleic acids.

[19]  Lei Chen,et al.  miR-221/222-Mediated Inhibition of Autophagy Promotes Dexamethasone Resistance in Multiple Myeloma. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  Yan Huang,et al.  LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p , 2019, Cell Death & Disease.

[21]  E. Giovannetti,et al.  Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma , 2018, Annals of surgery.

[22]  H. Bai,et al.  Long Non-Coding RNA MEG3 Functions as a Competing Endogenous RNA to Regulate HOXA11 Expression by Sponging miR-181a in Multiple Myeloma , 2018, Cellular Physiology and Biochemistry.

[23]  I. MacRae,et al.  Regulation of microRNA function in animals , 2018, Nature Reviews Molecular Cell Biology.

[24]  S. Monticelli,et al.  MicroRNAs as modulators of T cell functions in cancer. , 2018, Cancer letters.

[25]  A. Scorilas,et al.  Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer. , 2018, Annals of translational medicine.

[26]  G. Ahmann,et al.  Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients , 2018, Annals of Hematology.

[27]  O. Stephens,et al.  Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing , 2017, Nature Communications.

[28]  Huan Yao,et al.  LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma , 2017, Cell Death & Disease.

[29]  W. Zhou,et al.  Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma , 2017, Leukemia.

[30]  Zongguang Zhou,et al.  miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation. , 2017, Cancer letters.

[31]  Jinbang Li,et al.  miR-181a-5p, an inducer of Wnt-signaling, facilitates cell proliferation in acute lymphoblastic leukemia. , 2017, Oncology reports.

[32]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[33]  S. Rajkumar,et al.  New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma , 2016, Clinical Cancer Research.

[34]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[35]  R. Hájek,et al.  Centrosome associated genes pattern for risk sub-stratification in multiple myeloma , 2016, Journal of Translational Medicine.

[36]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[37]  Jian-jun Zhao,et al.  Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. , 2015, Cancer research.

[38]  Shuo Zhang,et al.  Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma , 2015, Tumor Biology.

[39]  K. Anderson,et al.  Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo , 2015, Leukemia.

[40]  Xiaowei Wang,et al.  miRDB: an online resource for microRNA target prediction and functional annotations , 2014, Nucleic Acids Res..

[41]  Xue-Qun Luo,et al.  miR-181a promotes G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM , 2015, Journal of Cancer Research and Clinical Oncology.

[42]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[43]  K. Qi,et al.  Potential relationship and clinical significance of miRNAs and Th17 cytokines in patients with multiple myeloma. , 2014, Leukemia research.

[44]  N. Munshi,et al.  Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth , 2013, Clinical Cancer Research.

[45]  K. Mimori,et al.  microRNA-181a is associated with poor prognosis of colorectal cancer. , 2012, Oncology reports.

[46]  N. Munshi,et al.  miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 , 2012, Cell Death and Disease.

[47]  M. Negrini,et al.  Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence , 2012, Clinical Cancer Research.

[48]  S. Schaffert,et al.  Modulating the Strength and Threshold of NOTCH Oncogenic Signals by mir-181a-1/b-1 , 2012, PLoS genetics.

[49]  Sebastian D. Mackowiak,et al.  miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades , 2011, Nucleic acids research.

[50]  Matko Bosnjak,et al.  REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.

[51]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[52]  Charles P. Lin,et al.  MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. , 2009, Blood.

[53]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[54]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[55]  C. Croce,et al.  miRNAs, Cancer, and Stem Cell Division , 2005, Cell.

[56]  D. Bartel,et al.  MicroRNAs Modulate Hematopoietic Lineage Differentiation , 2004, Science.

[57]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.